ConferenceSeries Ltd, the World Class Open Access Publisher and Scientific Event Organizer is delighted to host “6^th Global Gastroenterologists Meeting” during August 11-12, 2016 at Birmingham, UK. This gastrointestinal conference highlights the theme “Recent advancements and therapeutic techniques in the field of gastroenterology”. For more details please visit conference series.

ConferenceSeries Ltd organizes 300+ International Conferences every year across USA, Europe & Asia with support from 1000 more scientific Societies and publishes 400+ Open Access Journals which contains over 30000 eminent personalities, reputed scientists as editorial board members. 

Gastro 2016 mainly focuses on the latest diagnostic and therapeutic techniques for gastric diseases. This gastro conference discusses the latest research outcomes and technological advancements in the field and brings together leading gastroenterologists, surgeons, physicians, research scholars, students along with industrial and pharma professionals to exchange share their views on critical aspects of gastroenterology research. This gastroenterology conference brings together Presidents and Eminent Personalities to explore opportunities on emerging platforms in the field of gastrointestinal therapeutics. With members from around the world focused on learning about latest diagnostic and treatment procedures of various gastrointestinal diseases and all the related aspects of gastrointestinal diseases this is your best opportunity to reach the largest assemblage of participants from the entire world. From the workshop and speech in this gastroenterology conference from the eminent people of gastroenterology, you can update your knowledge about current situation of gastroenterology and receive name and recognition at this 2-day event. Gastro conference will help to provide platform to share ideas. World-renowned speakers with their ultimate talks on the most recent techniques, tactics, and the avant garde technologies in gastrointestinal therapeutics are the hallmarks of this gastroenterology conference. 

Gastrointestinal Carcinogenesis and Therapeutics

Gastrointestinal   Carcinogenesis as a group are the second most common cancers diagnosed in both men and women. Of all the GI cancers, colorectal cancer is the most common one amongst newly diagnosed GI cancers and pancreatic ductal adenocarcinoma is the most fatal one due to lack of early diagnosis and limited success of systemic therapeutics increased research activities towards development of novel therapeutics. Remarkable progress has been made in pathogenesis, biology, and molecular genetics of Gastric surgery.

Gastro cancer is managed by therapeutics with multi-disciplinary approach, involving several medical, surgical, radiological, pathological, gastroenterologists, hepatologists, and scientists. Key innovations and novel therapies have led to improved understanding of pathogenesis and achieve earlier detection, and advances in the management of Gastric banding and gastroplasty surgery. The most prevalent of gastrointestinal cancers is colorectal cancer in the Western world and gastric cancer in the Eastern world. Colorectal cancer is the third most common cancer in the world, with nearly 1.4 million new cases diagnosed in 2012 and Gastric cancer accounts for approximately 9,52,000 deaths each year worldwide. There are about 900 medical universities working on gastrointestinal cancers worldwide. This gastroenterology conference will provide a common place to be together and share their gastroenterology researches.

Inflammatory bowel disease Research vs Treatment / Management

The care of a patient with inflammatory bowel disease Research can be either medical or surgical in nature or, in many patients, a combination of both the treatment and Management of IBDR. The goals of therapy are the achievement of remission and the prevention of disease flares maintenance.

The concept of deep mucosal healing, particularly in Crohn’s disease, is becoming increasingly advocated. There are several studies, primarily involving anti-TNF agents and occasionally immune modifiers; that have shown that the elimination of inflammation as demonstrated by endoscopic and histologic criteria results in a decrease in the rate of surgery, the use of corticosteroids, and the rate of hospitalization.

The medical approach for patients with symptomatic care and mucosal healing following a stepwise approach to medication, with escalation of the medical regimen until a response is achieved.

Aminosalicylates, Antibiotics, Corticosteroids, Immunomodulators, Pharmacotherapy, Tumor necrosis factor inhibitors Monoclonal antibodies, UC is surgically curable. Crohn's disease and ulcerative colitis are the principal types of inflammatory bowel disease. In the United States, it is currently estimated that about 1-1.3 million people suffer from IBD. According to the Crohn's & Colitis Foundation of America, about 1.4 million Americans have Crohn’s disease or gastric ulcer. Of those, about 700,000 have Crohn’s. Gastro conference has a special eye to deal with Crohn’s disease.

Gastrointestinal Bleeding- Treatment and Management

Acute upper gastrointestinal bleeding is the most common gastroenterological emergency and has a considerable morbidity and mortality. Management strategies have changed dramatically over recent decades due to the introduction of acid suppressive therapy histamine-2 receptor antagonists and especially proton pump inhibitors and endoscopic therapy.

Patients with Gastrointestinal Bleeding can present with various symptoms such as hematemesis, hematochezia, melena, or progressive anemia. Immediate evaluation and appropriate treatment is of major importance in these patients. Laparoscopic gastric surgery is generally safe in the setting of gastrointestinal bleeding, as long as the patient has been sufficiently resuscitated before the procedure. Treatment and Management with scopy examinations summarized only one endoscopic complication perforation of a diverticulum was reported. A nasogastric tube can be used to administer this solution if the patient is unable to tolerate it by mouth. Those patients who have bled and apparently stopped, it is reasonable to administer the prep and perform the examination on an elective or semi elective basis. For those patients with continued hematochezia, the examination should be performed as soon as possible. GI bleeding results in 250,000 to 300,000 hospitalizations and 15,000 to 30,000 deaths per year in the United States. More than $2.5 billion is spent annually for inpatient care of this problem. 

Pancreatic diseases and Treatment

Pancreatic diseases are inflammation of the pancreas it also synthesizes and secretes insulin and glucon. Pancreatic or pancreatitis disease may be caused by gallstones, chronic alcohol use, trauma, medications, infections, tumors, and genetic abnormalities that is often severe and constant over several days, and may be accompanied by fever, nausea, vomiting, tachycardia and abdominal swelling.

Treatment for Pancreatitis is diagnosed preliminarily by physical exam and the levels of amylase and lipase in the blood. Other tests it may be done to detect gallstones or to identify the damaged pancreas and other blood tests may need to be done.

Gallstones may be removed using therapeutic endoscopic retrograde cholangiopancreatography (ERCP). This year, an estimated 48,960 adults (24,840 men and 24,120 women) in the United States will be diagnosed with pancreatic cancer. It is estimated that 40,560 deaths (20,710 men and 19,850 women) from this disease will occur this year. Pancreatic cancer is the eighth most common cancer in women and the fourth leading cause of cancer death in men and women.

Emerging therapies for Viral Hepatitis and Liver Fibrosis

Emerging therapies to treat viral hepatitis C virus (HCV) are evolving rapidly. With  the introduction of interferon‐α monotherapy based on triple therapies with pegylated interferon‐α and ribavirin , the chances of curing patients infected with HCV genotype 1 have improved from <10% to approximately 70%. 

Liver fibrosis occurs as a result of a wide range of injurious processes and in its end-stage results in cirrhosis. Indeed, liver fibrosis and cirrhosis represent a major worldwide healthcare burden. Recent progress in liver transplantation, the management of portal hypertension and the treatment of chronic viral hepatitis have had an important impact.

However, these approaches are not without their limitations – in particular, issues regarding organ availability for transplantation and serve to highlight the urgent requirement to influence pharmacologically the underlying fibrotic process in many patients. Gastro conference will be having a special session on Viral Hepatitis.

Treatment for Functional GI disorders

Functional Gastrointestinal  disorders remain a common problem in the pediatric age group, with pediatric gastro oncology. These conditions were first recognized  in 1958 when he coined the earlier term ‘recurrent abdominal pain’ (RAP) for a group of children with recurrent or persistent abdominal pain that interfered with functional daily living and had no evident organic etiology.

This review focuses on dietary, pharmacologic, cognitive behavioral and complementary medical treatment. IBS is most common in adults along with gastroenteritis and most of the treatments in the adult population have been geared toward treating that disorder.

Medications used to treat depression, anxiety, and seizures have become increasingly attractive agents for use in Functional Gastro Intestinal Disorders because they act upon the central and peripheral nervous system to modulate mood, visceral, and neuropathic pain, as well as autonomic function, in part, through anticholinergic effects.

Antidepressants such as tricyclic antidepressants (TCAs), serotonin reuptake inhibitors (SSRIs), and monoamine uptake inhibitors improve symptoms of IBS in adults. Antidepressants act by decreasing pain perception, improving mood and disturbed sleep patterns, and perhaps regulating motility. Of all the functional GI disorders, irritable bowel syndrome (IBS) is the most studied and among the most common. IBS is highly prevalent, affecting between 10–15% of the U.S. population. A Significant proportion – 35% to 40% of individuals who report IBS in the community are male and 60% to 65% of individuals who report IBS in the community are female.

Gastrointestinal Pharmacotherapy

Gastrointestinal Pharmacotherapy for functional gastrointestinal disorders, such as irritable bowel syndrome and functional dyspepsia, are complex conditions with multiple factors contributing to their pathophysiology. As a consequence and have posed significant challenges to the pharmaceutical industry when trying to develop new and effective treatments.

This review provides an overview of these difficulties and how the industry is reshaping its drug developmental strategies. It describes some of the more significant and encouraging advances that have occurred, and discusses how future research might embrace the opportunities provided by advances in genetic and in particular, epigenetic research.

Gastrointestinal Therapeutic Endoscopy- Advancements and Challenges

Advances in gastrointestinal Therapeutic endoscopic technology, with emphasis on imaging and treatment of disorders of the esophagus and small intestine and extend our knowledge regarding the endoscopic diagnosis of gastroesophageal reflux disease with the aid of endoscopic therapy and suggest new potential applications for biliary endoscopy.

Despite initial great enthusiasm for these procedures, the lack of well-done, controlled, prospective studies with clear endpoints and adequate follow-up has limited the current role for these modalities in our therapeutic arsenal against gastroesophageal reflux disease with advancements and challenges. In 2009, the U.S. market for GI endoscopic devices was valued at over $1.6 billion. This is an increase of nearly 5 percent from 2008. Nearly 23 million procedures were performed with GI endoscopic devices in 2009. More than 60 percent of these were colonoscopies. Virtual colonoscopies decreased by more than 7 percent in 2009 from 2008, but are expected to show notable growth over the next five years. 

Gastric Bypass Surgery- Types and Treatment

To test the feasibility of methods to conduct a larger multisite trial to determine the long-term effect of  gastric bypass surgery complications, Roux-en-Y gastric bypass  surgery compared with an intensive diabetes medical and weight management -Weight Achievement and Intensive Treatment  program for Type 2​ diabetes.

Use of NSAID’s and Antibiotic Therapy

The use of antibiotic therapy continues to increase as a result of accumulations of evidence of benefits in both primary and secondary treatment strategies for gastrointestinal disease. Gastrointestinal complications such as ulceration and related bleeding. These risks may be further compounded by the ancillary use of other adjunctive medications, such as nonsteroidal anti-inflammatory drugs (NSAID’s), corticosteroids, and anticoagulants. Given is the high prevalence of antiplatelet therapy in clinical practice, coupled with an increase emphasis on their extended use, especially after implantation of a drug-eluting stent, it is imperative that physicians know the potential benefits and the associated risks of antiplatelet therapy for primary or secondary prevention of cardiac ischemic events when combined with NSAID agents. Only with this understanding can physicians appropriately and fully evaluate the risk profile for each patient and either change medications or initiate prophylactic therapy in an attempt to reduce gastrointestinal complications.

Clinical Nutrition in Gastrointestinal Diseases

Food assimilation is the major function of the gastrointestinal tract. Many gastrointestinal diseases have important nutritional effects. Digestion and absorption of nutrients are discussed elsewhere. The focus will be on the role of the liver in regulating the supply of carbohydrate and lipid fuels as well as ensuring the availability of essential substrates to peripheral tissues. The clinical features of malnutrition and specific effects of malnutrition on the gastrointestinal tract and liver will be discussed along with diet therapy in gastrointestinal disease. Finally, an approach to clinical nutrition will be presented, including nutritional assessment and the rational use of enteral and parenteral nutritional support.

Traditional and Herbal Medications

Traditional medicine is the sum total of the knowledge, skills, and practices based on the theories, beliefs, and experiences indigenous to different cultures, whether explicable or not, used in the maintenance of health as well as in the prevention, diagnosis, improvement or treatment of physical and mental illness.

Herbal medications include herbs, herbal materials, herbal preparations and finished herbal products, which contain as active ingredients parts of plants, or other plant materials, or combinations.

Therapeutic activity refers to the successful prevention, diagnosis and treatment of physical and mental illnesses; improvement of symptoms of illnesses; as well as beneficial alteration or regulation of the physical and mental status of the body.

Probiotics as Gastrointestinal therapeutics

Probiotics are being used with increasing frequency as a treatment for several medical conditions, such as allergic diseases bacterial, renal diseases and renal cancer and urinary tract infections, and prevention of dental caries or respiratory infections. Probiotics are used as a treatment for a variety of gastrointestinal disorders. In this review, the historical perspectives, proposed mechanisms of action, formulations and delivery systems, safety, and specific GI disorders for which probiotics have been used are discussed.

Recent Advancements and Current research in Gastrointestinal Therapeutics

The present industry update, with information sourced from Gastrointestinal therapeutics companies regulatory and patent agencies as well as the current research on scientific literature. Despite this section being dedicated to recent advancements in ‘man-made’ drug research it is notable.

Conference Opportunities

For Researchers and Faculty Members:

Speaker Presentations
Poster Display
Symposium hosting (4-5 member team)
Workshop organizing

For Universities, Associations & Societies:

Association Partnering
Collaboration proposals
Academic Partnering
Group Participation

For Students and Research Scholars:

Poster Competition (Winner will get Best Poster Award)
Young Researcher Forum (YRF Award to the best presenter)
Student Attendee
Group registrations

For Business Delegates:

Speaker Presentations
Symposium hosting
Book Launch event
Networking opportunities
Audience participation

For Product Manufacturers:

Exhibitor and Vendor booths
Sponsorships opportunities
Product launch
Workshop organizing
Scientific Partnering
Marketing and Networking with clients

Summary

Gastro 2016 highlights the theme “Recent advancements and therapeutic techniques in the field of gastroenterology”. It mainly focuses on the latest diagnostic and therapeutic techniques for gastric diseases. It discusses the latest research outcomes and technological advancements in the field and brings together leading gastroenterologists, surgeons, physicians, research scholars, students along with industrial and pharma professionals to exchange share their views on critical aspects of gastroenterology research. There have been increases in the incidence of most gastrointestinal disorders in Europe which have major implications for future healthcare provision. Gastrointestinal cancer is the leading cause of cancer death in Europe. Recent studies of market value of GI therapeutics for major diseases in the eight major markets is expected to decrease in value from $6.8 billion in 2012 to $6.6 billion by 2019 forecasts business intelligence provider GBI Research. The major factors currently stabilizing the market include the increasing prevalence of GI diseases, growing awareness of the importance of detecting these diseases early and the availability of effective diagnostics creates an urgent need for organizing this gastroenterologists conference.

For more details please visit- http://gastro.conferenceseries.com/

Scope & Importance:

Gastro 2016 aims to bring together leading academic scientists, researchers and research scholars to exchange and share their experiences and research results about all aspects of gastro diseases. This gastro conference also provides the chance for researchers, practitioners and educators to present and discuss the most recent innovations, trends, and concerns, practical challenges encountered and the solutions adopted in the fields of Gastrointestinal therapeutics. It helps in promoting the advancement of gastroenterology. This gastro conferences provides a platform for organizations, companies, associations, societies, institutions, statutory bodies and other authorities and individuals interested in the causes, diagnosis, prevention and treatment of gastrointestinal diseases.

Gastroenterology is a specialty that tends to receive relatively little attention from a policy perspective and compared with other specialties, attracts relatively little charitable research funding. There have been increases in the incidence of most gastrointestinal disorders in Europe which have major implications for future healthcare provision. Gastrointestinal cancer is the leading cause of cancer death in Europe. It is also the most common cancer in men and the second most common in women after breast cancer. "Bariatric surgery conferences" is a general need for further research into the incidence, prognosis and public health burden of many gastrointestinal disorders across Europe and a particular need for more studies from Eastern Europe, along with pan-European and multinational studies.

Why Birmingham?

Birmingham was also one of the founding cities for the Euro cities group and is also sitting as chair. It is considered to be a Beta-global city, rated as the third most globally influential city in the UK after London and Manchester. Birmingham is home to one of the largest shopping centers in the UK, the Bullring. It is also the busiest in the UK, attracting 36.5 million visitors in its first year. Birmingham is the most visited retail destination outside London and the retail sector makes up a large proportion of the city's economy.

Conference Highlights:

·Gastrointestinal Carcinogenesis and Therapeutics

·Inflammatory Bowel Disease Treatment and Management

·Gastrointestinal Bleeding- Treatment and Management

·Colorectal diseases and treatment

·Emerging therapies for Liver diseases

·Treatment for Functional GI disorders

·Gastrointestinal Pharmacotherapy

·Gastrointestinal Therapeutic Endoscopy- Advancements and Challenges

·Gastric Bypass Surgery- Types and Treatment

·Use of NSAID’s and Antibiotic Therapy

·Clinical Nutrition for Gastrointestinal Diseases

·Traditional and Herbal Medications

·Probiotics as Gastrointestinal therapeutics

·Recent Advancements and Current research in Gastrointestinal Therapeutics

Why to attend???

With members from around the world focused on learning about latest diagnostic and treatment procedures of various gastrointestinal diseases and all the related aspects of gastrointestinal diseases this is your best opportunity to reach the largest assemblage of participants from the entire world. From the workshop and speech of the eminent people of gastro conferences 2016, you can update your knowledge about current situation of gastroenterology and receive name and recognition at this 3-day event. World-renowned speakers with their ultimate talks on the most recent techniques, tactics, and the avant garde technologies in gastrointestinal therapeutics are the hallmarks of this gastro conference 2016.

A Unique Opportunity for Advertisers and Sponsors at this International event:

http://gastro.conferenceseries.com/sponsors.php

Target Audience:

The target audience include Gastroenterologists, General practitioners, Pediatricians, Internal medicine specialists, Surgeons and participants from all leading universities, clinical research institutions and diagnostic service provider companies.

·Hospitals 30%

·Academia/Research60%

·Others 10%

Major Gastroenterology Associations around the Globe

·American Gastroenterological Association

·United European Gastroenterology

·Canadian Association of Gastroenterology (CAG)

·European Association for Gastroenterology, Endoscopy and Nutrition

·The Japanese Gastroenterological Association (JGA)

·IGA - Israel Gastroenterology Association

·Association of Gastroenterologists of Bosnia nad Herzegovina

·Bulgarian Association of Surgeons and Gastroenterologists

·European Crohns and Colitis Organisation

·Gastroenterohepatology Association of Montenegro - GAM

·The Australian and New Zealand Gastric and Oesophageal Surgery Association (ANZGOSA)

·Asian Pacific Association of Gastroenterology (APAGE)

·Ukrainian Association of Endoscopy

Major Gastroenterology Societies around the Globe

·Gastroenterological Society of Australia

·British society of Gastroenterology

·European Society of Gastrointestinal Endoscopy (ESGE)

·European Society for Paediatric Gastroenterology Hepatology and Nutrition (ESPGHAN)

·European society of Neuogastroenterology & Motility

·American Society for Gastrointestinal Endoscopy

·British society for Pediatric Gastroenterology, Hepatology and Nutrition

·North American society for Pediatric Gastroenterology, Hepatology and Nutrition

·Russian Society for Digestive Endoscopy

·Japanese Society of Gastroenterology

·Hong Kong Society of Gastroenterology 

·Hong Kong Society of Digestive Endoscopy

·Emirates Gastroenterology & Hepatology Society 

·Belgian Society of Gastroinestinal Endoscopy

·Cyprus Society of Gastroenterology

·Czech Gastroenterological Society

·Danish Society of Gastroenterology and Hepatology

·Korean Society of Gastroenterology

·Ohio Gastroenterology Society

Industries associated

Top Universities in UK:

·Birmingham City University

·University of Aston

·University of Birmingham

·Newman University, Birmingham

Major Universities around globe

•University of Oxford                                      

•University of Cambridge                               

•Harvard University                                       

•University of California, Berkeley (UCB)    

•Yale University                                                

•Princeton University                                      

•Stanford University                                        

•Columbia University                                       

•National University of Singapore (NUS)    

•UCL (University College London)                  

•University of Chicago                                      

•University of Toronto                                     

•Peking University

Universities associated

Global Market value of gastrointestinal therapeutics

Recent studies of market value of gastrointestinal therapeutics shows differences in different parts of the world. In 2012, the value of the gastrointestinal therapeutics market in major developed countries amounted to an estimated $6.8 billion. This total is forecast to decline at a Compound Annual Growth Rate (CAGR) of 0.3% between 2012 and 2019. The value of the IBS market amounted to an estimated $727m, and is forecast to increase at a CAGR of 14.4% between 2012 and 2019. The value of the UC market amounted to an estimated $2.2 billion in 2012, and is expected to increase at a CAGR of 6% during the forecast period. The value of the CD market amounted to an estimated $3.8 billion, which is expected to decline at a CAGR of 7.5% between 2012 and 2019.

Funding for Gastrointestinal therapeutics

Physician statistics

Health-care systems vary among countries and we were interested in how this might impact on gastroenterology manpower. The number of gastroenterologists in Canada and compared this with four countries where data were available over the Internet in either French or English. The number of gastroenterologists per 100,000 of the population was 3.9 in the United States, 3.48 in France, 2.1 in Australia, 1.83 in Canada, and 1.41 in the U.K. This variation in number of gastroenterologists was not reflected in the overall number of specialists per 100,000, which was similar in all five countries. Furthermore, the difference in gastroenterology manpower did not correlate with the amount of gross domestic product spent on health care. Countries with a low number of gastroenterologists per 100,000 all had a strong primary-care gatekeeper system, although this observation may be coincidental, as only five countries were studied. Canada had the most equitable distribution of gastroenterologists across the country with only modest differences among provinces. The United States had the most variation in the number of gastroenterologists per 100,000 of the population among states.

References:

1. http://www.marketresearch.com/product/sample-8026525.pdf

2. http://www.marketresearchreports.com/

3. http://www.medgadget.com/

4. http://www.prnewswire.com/

5. http://www.transparencymarketresearch.com/

6. http://www.businesswire.com/

7. https://www.cag-acg.org